Eton Pharmaceuticals (ETON) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Schrodinger (SDGR) over the past year, gaining 269.7% versus a gain of 39.2%. Over five years, ETON leads with a +1341.9% price change compared with -42.0% for SDGR. Eton Pharmaceuticals is the larger company by market cap ($1.76 billion vs $1.72 billion), about 1.0 times the size.
Eton Pharmaceuticals converts more of its revenue into profit, with a net margin of -5.8% versus -40.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | SDGR |
|---|---|---|
| Share price | $60.85 | $22.93 |
| Market cap | $1.76B | $1.72B |
| 1-day change | -0.83% | -12.95% |
| YTD return | +259.85% | +28.24% |
| 1-year return | +269.68% | +39.22% |
| 5-year return | +1341.94% | -42.01% |
| P/E ratio (TTM) | 39.51 | — |
| Forward P/E | 18.41 | — |
| EPS (TTM) | $1.54 | $-0.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $79.95M | $255.87M |
| Revenue growth (YoY) | +104.94% | +23.29% |
| Net income (latest FY) | $-4.60M | $-103.27M |
| Gross margin | 53.46% | 55.74% |
| Operating margin | -1.06% | -65.23% |
| Net margin | -5.75% | -40.36% |
| 52-week high | $70.64 | $34.00 |
| 52-week low | $14.27 | $10.95 |
| Distance from 52-week high | -13.86% | -32.56% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +32.70% | +46.40% |
| Average volume | 570.79K | 2.08M |
| Shares outstanding | 28.84M | 65.91M |
| Employees | 44 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed SDGR by 230.5 percentage points over the past year.
- Eton Pharmaceuticals is more profitable, keeping -5.8 cents of every revenue dollar as net income versus -40.4 cents for Schrodinger.
- Eton Pharmaceuticals grew revenue faster in its latest fiscal year (+104.94% vs +23.29%).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
ETON vs SDGR FAQ
Which is bigger, Eton Pharmaceuticals or Schrodinger?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.76B compared with $1.72B for Schrodinger (SDGR).
Which stock has performed better over the past year, ETON or SDGR?
ETON returned +269.68% over the past 12 months, compared with +39.22% for SDGR (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.